WuXi Biologics (HKG: 2269), a Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has announced the launch of a new mammalian cell line construction technology platform named WuXiaADCC PLUS. This platform is designed to be an efficient, high-yield, and high Antibody Dependent Cell Mediated Cytotoxicity (ADCC) activity platform for the development and production of non-fucosylated antibodies.
The industry consensus is that ADCC plays a pivotal role in targeted antibody-based immunotherapy. Enhancing the ADCC effect through antibody design and engineering modifications is one of the current directions in the development of new cancer therapies. The removal of fucose modification on N-glycosylation sites to enhance the ADCC effect is anticipated to improve the efficacy of antibody immunotherapy.- Flcube.com
